Skip to main content
. 2020 Mar 10;10:31. doi: 10.1186/s13578-020-00396-1

Table 1.

Summary of the research phase of the mTOR inhibitors

mTOR inhibitors Applied tumor Phase References
Everolimus RCC FDA approved
Temsirolimus Advanced RCC FDA approved
ICSN3250 Colon cancer cell Pre-clinical studies Nguyen et al. [53]
LY3023414 Solid tumor or lymphoma Phase I clinical trial Bendell et al. [54]
OSU-53 Thyroid cancer cell Pre-clinical studies Plews et al. [55]
AZD8055 OCCC cell Pre-clinical studies Caumanns et al. [59]
Everolimus Aggressive and RAIR thyroid cancer Phase II clinical trial Hanna et al. [60]
Rapamycin Pancreatic cancer Pre-clinical studies Morran et al. [61]
Temsirolimus PCNSL Phase II clinical trial Korfel et al. [62]

RCC renal cell carcinoma, OCCC ovarian clear cell carcinoma, RAIR radioactive iodine-refractory, PCNSL primary central nervous system lymphoma, FDA Food and Drug Administration